Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -5.10% is 5985% below its 5-year average of 0.09%, around the middle of its 5-year range (-18.18%–19.40%).
As of the fiscal period ended Tuesday, September 30, 2025. 20.28% below its 12-month average of -4.24%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-09-30.
RETURN ON EQUITY (ROE)
-5.10%
RETURN ON EQUITY (ROE) AVG TTM
-4.24%
RETURN ON EQUITY (ROE) AVG 3Y
-6.16%
RETURN ON EQUITY (ROE) AVG 5Y
0.09%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-20.28%
CURRENT VS 3Y AVG
+17.17%
CURRENT VS 5Y AVG
-5984.62%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.33%
median of 447 covered companies
CURRENT VS SECTOR MEDIAN
+86.69%
vs the sector median at left
BGM Group Ltd.
Market Cap
$118.63M
Return on Equity (ROE)
-5.10%
TTM Avg
-4.24%
3Y Avg
-6.16%
5Y Avg
0.09%
Market Cap
$120.44M
Return on Equity (ROE)
N/A
TTM Avg
326.93%
3Y Avg
83.50%
5Y Avg
24.39%
Market Cap
$121.00M
Return on Equity (ROE)
-165.57%
TTM Avg
-146.09%
3Y Avg
30.63%
5Y Avg
465.14%
Market Cap
$118.02M
Return on Equity (ROE)
-105.40%
TTM Avg
-90.09%
3Y Avg
-60.23%
5Y Avg
-18.64%
Market Cap
$117.43M
Return on Equity (ROE)
N/A
TTM Avg
129.36%
3Y Avg
-24207.46%
5Y Avg
-16163.58%
Market Cap
$115.69M
Return on Equity (ROE)
-209.73%
TTM Avg
-196.07%
3Y Avg
-130.72%
5Y Avg
-67.26%
Market Cap
$115.55M
Return on Equity (ROE)
-93.44%
TTM Avg
-8.16%
3Y Avg
13.24%
5Y Avg
13.24%
Market Cap
$114.00M
Return on Equity (ROE)
-0.05%
TTM Avg
-43.47%
3Y Avg
9.13%
5Y Avg
-18.50%
Market Cap
$112.88M
Return on Equity (ROE)
-57.47%
TTM Avg
-26.63%
3Y Avg
16.73%
5Y Avg
210.40%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BGM Group Ltd. (BGM) | $118.63M | -5.10% | -4.24% | -6.16% | 0.09% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $120.44M | N/A | 326.93% | 83.50% | 24.39% |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.00M | -165.57% | -146.09% | 30.63% | 465.14% |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | -105.40% | -90.09% | -60.23% | -18.64% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | N/A | 129.36% | -24207.46% | -16163.58% |
| Genelux Corporation (GNLX)vs › | $115.69M | -209.73% | -196.07% | -130.72% | -67.26% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.55M | -93.44% | -8.16% | 13.24% | 13.24% |
| Coya Therapeutics, Inc. (COYA)vs › | $114.00M | -0.05% | -43.47% | 9.13% | -18.50% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $112.88M | -57.47% | -26.63% | 16.73% | 210.40% |
| enGene Holdings Inc. (ENGN)vs › | $125.27M | -2.13% | -45.09% | -61.80% | -44.27% |
ROE
-5.1%
ROA
-4.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-09-30 | -5.10% |
| 2024-09-30 | -3.38% |
| 2023-09-30 | -18.18% |
| 2022-09-30 | 2.03% |
| 2021-09-30 | 5.75% |
| 2020-09-30 | 19.40% |
| 2019-09-30 | 26.80% |
| 2018-09-30 | 33.74% |
| 2017-09-30 | 12.58% |
